Switching From Semaglutide to Tirzepatide on a Microdose: Dose Conversion, Timing, and What the Switch Studies Show

People move from semaglutide to tirzepatide for a handful of reasons. Weight loss stalls. Side effects never settle. A prescriber wants the extra GIP action. Or the price moves: a 2026 study of more than a million UK adults showed switching patterns shifting sharply after a tirzepatide list-price rise of up to 170% in September 2025.

This article covers what the FDA prescribing information for Zepbound and Wegovy says about starting tirzepatide, what the SURMOUNT-5 head-to-head trial found, and what the small number of real switch studies show. One limit applies throughout. Every study here used labeled doses. Nobody has tested a switch that starts or ends at a microdose, so the evidence below is a guide to the shape of a switch, not a tested microdose recipe.

Is there a semaglutide to tirzepatide dose conversion?

There is no official semaglutide to tirzepatide dose conversion. The Zepbound prescribing information gives one starting dose for everyone, 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on each dose. Maintenance is 5, 10 or 15 mg. The label does not offer a faster start for people arriving from semaglutide.

The closest thing to a conversion comes from modelling. Builes-Montaño and colleagues, writing in Diabetes Therapy (2026), pooled 48 trial arms covering 16,524 people with type 2 diabetes. Using an equivalence margin of 2 percentage points of weight loss, they estimated a 99.4% probability that semaglutide 2.4 mg and tirzepatide 10 mg perform the same, and 94.8% for semaglutide 7.2 mg against tirzepatide 15 mg.

The same paper found that lower semaglutide doses were not equivalent to higher tirzepatide doses. That matters for microdosing. The pairings that matched sit at full maintenance doses, in people with diabetes, and the study was partly authored by Novo Nordisk staff. It says nothing reliable about how a sub-label semaglutide dose maps onto tirzepatide.

How much more weight loss does tirzepatide give than semaglutide?

At maximum tolerated doses, tirzepatide produced clearly more weight loss than semaglutide in the only head-to-head obesity trial. SURMOUNT-5, reported by Aronne and colleagues in the New England Journal of Medicine (2025), randomized 751 adults with obesity but without type 2 diabetes to tirzepatide 10 or 15 mg or semaglutide 1.7 or 2.4 mg for 72 weeks.

Weight fell by 20.2% on tirzepatide and 13.7% on semaglutide. Waist circumference fell by 18.4 cm and 13.0 cm. A later post hoc analysis in the American Journal of Medicine (2026) looked at speed: 44% of tirzepatide users and 21% of semaglutide users lost at least 15% of their weight by week 24.

SURMOUNT-5 compared people who started on one drug or the other. It did not test switching, and its doses sit far above microdose ranges. For a dose-by-dose look at the lowest trial doses of each drug, see our comparison of microdose semaglutide vs tirzepatide.

What do the semaglutide to tirzepatide switch studies show?

The switch studies are small, retrospective and done in people with type 2 diabetes, and only one of them reports the starting dose: 2.5 mg. Kurinami and colleagues, in Endocrinology and Metabolism (2025), followed 15 Japanese adults who moved from semaglutide 1.0 mg because of inadequate weight loss. All began tirzepatide at 2.5 mg and were escalated to 7.5 mg (n=10) or 10 mg (n=5).

Over 3 months, the 10 mg group saw HbA1c fall by 0.7% and a weight trend of -6.6 kg that did not reach statistical significance. The 7.5 mg group showed no significant change. With 15 people, those results are a signal, not a finding.

The larger Hokkaido-TZP analysis by Takiyama and colleagues in the Journal of Diabetes and its Complications (2026) followed 182 people with type 2 diabetes for 6 months after switching from a GLP-1 receptor agonist to tirzepatide. HbA1c, body weight and liver enzymes all fell after the switch. There was no comparison group that stayed on the old drug, so some of that change could reflect time or closer follow-up.

Outside diabetes, switching is less common than many people assume. In a Johns Hopkins record review of 9,189 adults without diabetes who started semaglutide or tirzepatide, published in Diabetes, Obesity and Cardiometabolism CARE (2026), only 18.6% held prescriptions for 336 days or more, and switches to another GLP-1 medicine were rare. Stopping was the more common event.

How long should you wait between the last semaglutide dose and the first tirzepatide dose?

Neither label sets a waiting period between the two drugs, and the published switch studies did not describe a washout. What the labels do set is a ban on overlap. The Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended, and the Wegovy prescribing information says the same about combining semaglutide with any other GLP-1 receptor agonist.

The half-lives explain why timing still matters. The Wegovy label gives semaglutide an elimination half-life of approximately 1 week and says it remains in the circulation for about 5 to 7 weeks after the last injection. The Zepbound label gives tirzepatide a half-life of approximately 5 days.

In practice this means a first tirzepatide dose given on the next weekly injection day lands on top of semaglutide that is still fading. No study has compared an immediate switch with a longer gap, at full doses or at microdoses, so the timing is one to agree with the prescriber. Our article on restarting a GLP-1 microdose after a break covers what happens when the gap grows to two weeks or more.

Will nausea and other side effects come back after switching?

Nausea and other gastrointestinal side effects can come back after a switch, because both drugs cause them mainly during dose escalation and a switch starts a new ladder. The SURMOUNT-5 paper states that GI events in both arms were mostly mild to moderate and occurred primarily during dose escalation.

In the Zepbound label, nausea affected 8% on placebo and 25%, 29% and 28% on 5, 10 and 15 mg. Diarrhea rose from 8% to 19%, 21% and 23%. The Wegovy label reports nausea in 44% of people on semaglutide 2.4 mg against 16% on placebo, and diarrhea in 30% against 16%.

These rates come from separate trial programmes and cannot be compared head to head. They also describe full doses. Starting tirzepatide low is the labeled way to limit the return of nausea, and our guide to managing nausea on a GLP-1 microdose covers the practical side if it does.

What else changes when you switch from semaglutide to tirzepatide?

Starting tirzepatide restarts two label safety clocks that semaglutide users may have stopped thinking about. The first is contraception. The Zepbound label says people on oral hormonal contraceptives should switch to a non-oral method, or add a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. A switch counts as starting. Our article on birth control on a GLP-1 microdose explains why.

The second is other medicines with narrow margins. Burson and Leung, writing in the Mental Health Clinician (2026), described a 23-year-old on lithium whose level rose from 0.9 to 1.7 mEq/L after switching from semaglutide to tirzepatide, with symptoms starting 4 days after the first tirzepatide dose. It is a single case report, but the authors recommended closer lithium monitoring whenever these drugs are started, changed or switched.

The missed-dose rule changes too. The Zepbound label allows a late dose within 4 days (96 hours), while the Wegovy injection rule counts forward and skips the dose if the next one is less than 2 days away. A switch is a good moment to write the new rule down.

Does switching back from tirzepatide to semaglutide work the same way?

Switching back follows the same label logic in reverse: no conversion table, no overlap, and the Wegovy label starts semaglutide at 0.25 mg once weekly for 4 weeks before titrating every 4 weeks toward 2.4 mg. Reverse switches are happening at scale. In the UK cohort of 1,033,522 adults reported in Diabetes, Obesity and Metabolism (2026), tirzepatide-to-semaglutide switching rose by 9.26 percentage points after the September 2025 price increase.

The same cohort reported estimated 12-month weight loss of 19.93% on tirzepatide and 16.40% on semaglutide. That was a telehealth population with little added lifestyle support, observed rather than randomized, and it did not report results for the people who switched.

Frequently asked questions

Clinical references

1. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed. 2026. dailymed.nlm.nih.gov
2. Novo Nordisk. WEGOVY (semaglutide) injection and tablet, prescribing information. DailyMed. 2026. dailymed.nlm.nih.gov
3. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2416394
4. Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. American Journal of Medicine. 2026. doi:10.1016/j.amjmed.2026.03.010
5. Kurinami N, Takada M, Sugiyama S, et al. Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus. Endocrinology and Metabolism. 2025. doi:10.3803/EnM.2025.2420
6. Takiyama T, Kitsunai H, Maruyama F, et al. Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study. Journal of Diabetes and its Complications. 2026. doi:10.1016/j.jdiacomp.2026.109391
7. Builes-Montaño CE, Suarez-Rodriguez AF, Alzate-Vinasco MA. Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis. Diabetes Therapy. 2026. doi:10.1007/s13300-026-01886-0
8. Ali D, Kudaya D, Ngige A, Chao AM. Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity. Diabetes, Obesity and Cardiometabolism CARE. 2026. doi:10.2337/doc25-0026
9. Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71410
10. Burson JR, Leung JG. Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management. Mental Health Clinician. 2026. doi:10.9740/mhc.2026.02.034